Akili (NASDAQ:AKLI) versus Presbia (OTCMKTS:LENSF) Financial Comparison

Presbia (OTCMKTS:LENSF) and Akili (NASDAQ:AKLI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Presbia and Akili, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Presbia	0	0	0	0	N/A
Akili	0	0	1	0	3.00

Akili has a consensus target price of $4.00, indicating a potential upside of 825.93%. Given Akili’s higher possible upside, analysts clearly believe Akili is more favorable than Presbia.

Risk & Volatility

Presbia has a beta of 5.91, meaning that its share price is 491% more volatile than the S&P 500. Comparatively, Akili has a beta of 1.72, meaning that its share price is 72% more volatile than the S&P 500.

Profitability

This table compares Presbia and Akili’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Presbia	N/A	N/A	N/A
Akili	-2,492.04%	-79.93%	-59.16%

Institutional and Insider Ownership

53.1% of Akili shares are held by institutional investors. 74.2% of Presbia shares are held by company insiders. Comparatively, 10.1% of Akili shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Presbia and Akili’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Presbia	N/A	N/A	N/A	N/A	N/A
Akili	$1.95 million	17.46	-$59.49 million	($0.61)	-0.71

Presbia has higher earnings, but lower revenue than Akili.

Summary

Presbia beats Akili on 5 of the 9 factors compared between the two stocks.

About Presbia

Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in the United States, South Korea, Australia, Italy, the Netherlands, Ireland, Canada, and Germany. The company was founded in 2014 and is headquartered in Dublin, Ireland.

About Akili

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.